$12.2659
Insights on Acorda Therapeutics, Inc.
Revenue is down for the last 2 quarters, 29.67M → 27.71M (in $), with an average decrease of 6.6% per quarter
Netprofit is up for the last 3 quarters, -16.82M → -8.88M (in $), with an average increase of 42.4% per quarter
In the last 1 year, Zoetis Inc. has given 20.3% return, outperforming this stock by 13.7%
In the last 3 years, Neurocrine Biosciences Inc. has given 15.7% return, outperforming this stock by 102.1%
2.12%
Downside
Day's Volatility :10.37%
Upside
8.43%
96.34%
Downside
52 Weeks Volatility :97.53%
Upside
32.58%
Period | Acorda Therapeutics, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -8.41% | -0.7% | 0.0% |
6 Months | 21.69% | 1.3% | 0.0% |
1 Year | 9.52% | -4.3% | -1.5% |
3 Years | -86.37% | 18.3% | -7.5% |
Market Capitalization | 12.9M |
Book Value | $47.47 |
Dividend Share | 0.0 |
Dividend Yield | 1.86% |
Earnings Per Share (EPS) | 2.61 |
PE Ratio | 3.98 |
PEG Ratio | 0.51 |
Wall Street Target Price | 10.0 |
Profit Margin | -14.36% |
Operating Margin TTM | -27.86% |
Return On Assets TTM | -3.32% |
Return On Equity TTM | -23.68% |
Revenue TTM | 111.1M |
Revenue Per Share TTM | 87.94 |
Quarterly Revenue Growth YOY | -17.299999999999997% |
Gross Profit TTM | 82.4M |
EBITDA | 11.5M |
Diluted Eps TTM | 2.61 |
Quarterly Earnings Growth YOY | 5.87 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Downside of 18.47%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 588.3M | ↑ 13.22% |
Net Income | -223.4M | ↑ 545.21% |
Net Profit Margin | -37.97% | ↓ 31.31% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 471.4M | ↓ 19.86% |
Net Income | 33.7M | ↓ 115.08% |
Net Profit Margin | 7.14% | ↑ 45.11% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 192.4M | ↓ 59.19% |
Net Income | -273.0M | ↓ 910.42% |
Net Profit Margin | -141.87% | ↓ 149.01% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 153.0M | ↓ 20.5% |
Net Income | -99.6M | ↓ 63.51% |
Net Profit Margin | -65.11% | ↑ 76.76% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 129.1M | ↓ 15.62% |
Net Income | -104.0M | ↑ 4.38% |
Net Profit Margin | -80.54% | ↓ 15.43% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 118.6M | ↓ 8.14% |
Net Income | -65.9M | ↓ 36.59% |
Net Profit Margin | -55.59% | ↑ 24.95% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 31.1M | ↑ 37.8% |
Net Income | -46.7M | ↑ 90.37% |
Net Profit Margin | -150.34% | ↓ 41.52% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 33.5M | ↑ 7.92% |
Net Income | -13.9M | ↓ 70.32% |
Net Profit Margin | -41.34% | ↑ 109.0% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 31.5M | ↓ 6.08% |
Net Income | 19.1M | ↓ 238.18% |
Net Profit Margin | 60.83% | ↑ 102.17% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 22.3M | ↓ 29.28% |
Net Income | -16.8M | ↓ 187.88% |
Net Profit Margin | -75.59% | ↓ 136.42% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 29.7M | ↑ 33.32% |
Net Income | -9.4M | ↓ 44.24% |
Net Profit Margin | -31.61% | ↑ 43.98% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 27.7M | ↓ 6.6% |
Net Income | -8.9M | ↓ 5.26% |
Net Profit Margin | -32.07% | ↓ 0.46% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 1.2B | ↓ 10.75% |
Total Liabilities | 678.0M | ↓ 0.02% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.3B | ↑ 8.49% |
Total Liabilities | 687.7M | ↑ 1.43% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 799.7M | ↓ 38.47% |
Total Liabilities | 488.9M | ↓ 28.91% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 632.7M | ↓ 20.89% |
Total Liabilities | 394.7M | ↓ 19.26% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 455.5M | ↓ 28.01% |
Total Liabilities | 304.3M | ↓ 22.9% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 395.6M | ↓ 13.15% |
Total Liabilities | 302.0M | ↓ 0.78% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 406.3M | ↓ 4.2% |
Total Liabilities | 318.4M | ↑ 7.36% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 393.3M | ↓ 3.19% |
Total Liabilities | 317.6M | ↓ 0.26% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 395.6M | ↑ 0.57% |
Total Liabilities | 302.0M | ↓ 4.91% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 374.9M | ↓ 5.23% |
Total Liabilities | 297.9M | ↓ 1.33% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 364.7M | ↓ 2.72% |
Total Liabilities | 296.8M | ↓ 0.38% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 366.3M | ↑ 0.45% |
Total Liabilities | 307.4M | ↑ 3.56% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 96.5M | ↑ 173.01% |
Investing Cash Flow | -10.7M | ↓ 85.48% |
Financing Cash Flow | 61.5M | ↑ 33.94% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 150.8M | ↑ 56.26% |
Investing Cash Flow | -176.9M | ↑ 1550.94% |
Financing Cash Flow | 12.8M | ↓ 79.2% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -128.2M | ↓ 185.0% |
Investing Cash Flow | -505.0K | ↓ 99.71% |
Financing Cash Flow | -60.6M | ↓ 573.16% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -61.0M | ↓ 52.4% |
Investing Cash Flow | 59.4M | ↓ 11854.46% |
Financing Cash Flow | -1.7M | ↓ 97.25% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -41.3M | ↓ 32.22% |
Investing Cash Flow | 73.8M | ↑ 24.29% |
Financing Cash Flow | -69.7M | ↑ 4075.96% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -20.9M | ↓ 49.4% |
Investing Cash Flow | -136.0K | ↓ 100.18% |
Financing Cash Flow | 0.0 | ↓ 100.0% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -14.5M | ↑ 6.43% |
Investing Cash Flow | -70.0K | ↑ 79.49% |
Financing Cash Flow | 0.0 | - |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -1.8M | ↓ 87.33% |
Investing Cash Flow | -150.0K | ↑ 114.29% |
Financing Cash Flow | -1000.0 | - |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 9.1M | ↓ 592.99% |
Investing Cash Flow | 123.0K | ↓ 182.0% |
Financing Cash Flow | 1000.0 | ↓ 200.0% |
Sell
Neutral
Buy
Acorda Therapeutics, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Acorda Therapeutics, Inc. | 28.17% | 21.69% | 9.52% | -86.37% | -99.37% |
![]() Neurocrine Biosciences Inc. | 6.38% | 25.45% | -1.84% | 30.01% | 36.75% |
![]() Haleon Plc Spon Ads | 2.25% | 0.74% | 5.27% | 10.53% | 10.53% |
![]() Zoetis Inc. | 9.34% | 11.51% | 20.76% | 15.71% | 105.57% |
![]() Viatris Inc. | 9.83% | 4.57% | -11.76% | -43.31% | -39.84% |
![]() Catalent, Inc. | 12.33% | -13.09% | -18.29% | -60.96% | 2.51% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Acorda Therapeutics, Inc. | 3.98 | 3.98 | 0.51 | 0.0 | -0.24 | -0.03 | 0.02 | 47.47 |
![]() Neurocrine Biosciences Inc. | 61.64 | 61.64 | 1.87 | 2.29 | 0.11 | 0.09 | 0.01 | 20.39 |
![]() Haleon Plc Spon Ads | 25.24 | 25.24 | 3.06 | 0.41 | 0.06 | 0.04 | 0.01 | 1.78 |
![]() Zoetis Inc. | 36.48 | 36.48 | 2.99 | 5.42 | 0.47 | 0.14 | 0.01 | 11.05 |
![]() Viatris Inc. | 6.19 | 6.19 | NA | 2.95 | 0.09 | 0.03 | 0.05 | 17.39 |
![]() Catalent, Inc. | 211.02 | NA | 2.63 | 1.01 | -0.22 | 0.0 | 0.0 | 21.58 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Acorda Therapeutics, Inc. | Buy | $12.9M | -99.37% | 3.98 | -14.36% |
![]() Neurocrine Biosciences Inc. | Buy | $11.5B | 36.75% | 61.64 | 10.71% |
![]() Haleon Plc Spon Ads | Buy | $39.6B | 10.53% | 25.24 | 11.05% |
![]() Zoetis Inc. | Buy | $82.2B | 105.57% | 36.48 | 27.24% |
![]() Viatris Inc. | Hold | $11.2B | -39.84% | 6.19 | 11.84% |
![]() Catalent, Inc. | Hold | $7.2B | 2.51% | 211.02 | -22.36% |
Davidson Kempner Capital Management LP
Renaissance Technologies Corp
Acadian Asset Management LLC
Vanguard Group Inc
BlackRock Inc
Wells Fargo & Co
acorda therapeutics is a publicly traded (nasdaq: acor) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. we started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. we have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. we achieve our goals by: • investing in research and development • collaborating closely with the patient, medical and scientific communities • retaining employees with compassion and commitment acorda has been voted one of the best companies to work for in new york for the past five years in a row, as a result of our dynamic environment, strong corporate
Organization | Acorda Therapeutics, Inc. |
Employees | 111 |
CEO | Dr. Ron Cohen M.D. |
Industry | Health Technology |
Asymmetric Smart Alpha S&p 500 Etf
$12.27
-2.03%
Advisorshares Alpha Dna Equity Sentiment Etf
$12.27
-2.03%
Falcon's Beyond Global Inc
$12.27
-2.03%
Jaguar Global Growth Corporation I
$12.27
-2.03%
Missfresh Ltd
$12.27
-2.03%
Shuaa Partners Acquisition Corp I
$12.27
-2.03%
Rose Hill Acquisition Corp
$12.27
-2.03%
Partners Bancorp
$12.27
-2.03%
Bsquare Corp
$12.27
-2.03%